Clinical trial NCT05520567: A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Official title: A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive Induction Chemotherapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia
Keywords: Cancer
Acute Myeloid Leukemia
AML
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2022-08-30
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene.

Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with AML with the changed FLT3 gene. They cannot have chemotherapy due to old age or other conditions. Before these combined 3 medicines are available as a treatment, the researchers need to understand how they are processed by and act upon the body when given together. In this study, they do this to find a suitable dose for venetoclax and to check for potential medical problems from the treatment.

In this study, people newly diagnosed with AML who have the changed FLT3 gene and cannot have chemotherapy can take part.

The main aims of this study are: to find suitable doses of gilteritinib, venetoclax and azacitidine as a combined treatment; to learn how they are processed by and act upon the body; to learn the remission rate; to check for medical problems during this treatment.

In the study, people will visit the study clinic many times. The first visit is to check if they can take part. People will be asked about their medical history, have a medical examination, and have their vital signs checked. Also, they will have an ECG to check their heart rhythm and have some blood and urine samples taken for laboratory tests. They will have a chest X-ray and a bone marrow sample will be taken. The changed FLT3 gene will be confirmed, either by the bone marrow or a blood sample.

This study will be in 2 phases.

In Phase 1, different small groups of people will take venetoclax tablets containing lower to higher doses in the combined treatment. The doses of gilteritinib and azacytidine will be unchanged. This is done to find a suitable dose of venetoclax to use in phase 2 of the study. People will take tablets of gilteritinib and venetoclax once a day on a 28-day cycle. They will be given azacytidine as an infusion or an injection just under the skin. This will be for 7 days at the beginning of each 28-day cycle. They will continue cycles of treatment throughout this phase of the study.

In Phase 2, more people newly diagnosed with AML with the changed FLT3 gene will take part. They will be treated with the suitable doses of the combined treatment worked out from Phase 1. Treatment will be on a 28-day cycle. People will continue on cycles of treatment throughout this phase of the study.

Researchers will work out the remission rate from this phase of the study. In each phase of the study, people can continue with up to 12 cycles of treatment if they can manage any medical problems. People will visit the study clinic many times during their first treatment cycle, and less often during the next cycles. During these visits, medical problems will be recorded and some blood samples will be taken for laboratory tests. On some visits, people will also have their vital signs checked. Bone marrow samples will be taken during cycle 1, and at the beginning of cycle 3. More samples will be taken during the study from people who are not in remission.

When people have finished treatment, those who have responded well to treatment and are in remission will be invited to continue with up to 24 more cycles of gilteritinib plus azacitidine.

All people taking part in the study will visit the study clinic for an end-of-treatment visit. During this visit, medical problems will be recorded and some blood samples will be taken for laboratory tests. People will have a medical examination, an ECG, and will have their vital signs checked. Also, a bone marrow sample will be taken. There will be a follow-up visit 30 days later to check for medical problems. Then people will visit the clinic or get a phone call every 3 months for up to 3 years. This is to give an update on their current treatment for AML.

Some people can have a stem cell transplant during the study if they meet certain study rules. They will pause their study treatment during the stem cell transplant process and continue study treatment afterwards.


Eligibility criteria: Inclusion Criteria

* Participant has a diagnosis of previously untreated Acute Myeloid Leukemia (AML) according to World Health Organization classification as determined by pathology review at the treating institution.
* Participant is positive for FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication \[ITD\] and/or tyrosine kinase domain \[TKD\] \[D835/I836\] mutation) in bone marrow or whole blood as determined by the central laboratory. A participant with rapidly proliferative disease and unable to wait for the central laboratory results can be enrolled from a local test result.
* Participant is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:

  * Participant is \>= 75 years of age with Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  * Participant is \>= 18 to 75 years of age and has any of the following comorbidities: ECOG performance status 2 or 3, cardiac history of congestive heart failure requiring treatment or ejection fraction \<= 50% or chronic stable angina, known history of diffusion capacity of lung for carbon monoxide (DLCO) \<= 65% or forced expiratory volume in the first second (FEVI) \<= 65%, creatinine clearance \> 30 mL/min to 45 mL/min, calculated by the Cockcroft Gault formula, moderate hepatic impairment with total bilirubin \> 1.5 to \< 3.0 x upper limit of normal (ULN), any other comorbidity incompatible with intensive chemotherapy during screening and before enrollment.
* Participant must have a projected life expectancy of at least 12 weeks.
* Participant must have adequate organ and bone marrow function prior to enrollment, as specified per protocol's laboratory parameters.
* Participant is suitable for oral administration of study drug (gilteritinib and venetoclax) and is willing/able to swallow oral tablets/capsules.
* Participant with a known history of human immunodeficiency virus (HIV) on effective antiretroviral therapy must have a viral load undetectable for 6 months prior to Cycle 1 Day 1 (C1D1).
* Female participant is eligible to participate if she is not pregnant and at least one of the following conditions apply:

  * Not a woman of childbearing potential (WOCBP) OR
  * WOCBP agrees to follow the contraceptive guidance starting at screening and continue through the study treatment period, and for at least 180 days after the final study regimen administration.

WOCBP must have a negative pregnancy test during screening.

* Female participant must agree not to breastfeed starting at screening, throughout the study treatment period and for 60 days after the last dose of the study treatment regimen.
* Female participant must not donate ova starting at screening, throughout the study treatment and for 180 days after the last dose of the study treatment regimen.
* Male participant with female partner(s) of childbearing potential must agree to use contraception starting at screening and continue through the study treatment, and for at least 120 days after the last dose of the study treatment regimen.
* Male participant must not donate sperm starting at screening, throughout the study treatment and for 120 days after the last dose of the study treatment regimen. (Venetoclax may cause a decrease in spermatogenesis. Male participant considering preservation of fertility should bank sperm before initiating treatment with venetoclax.)
* Male participant with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for 120 days after the final study drug administration.
* Participant agrees not to participate in another interventional study while on treatment in this study.

Exclusion Criteria:

* Participant with the following conditions:

  * Acute promyelocytic leukemia (APL)
  * Active, symptomatic central nervous system (CNS) involvement with AML
  * History of myeloproliferative neoplasm (MPN), including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation or AML with BCR-ABL1 translocation
* Participant previously treated with CAR-T cell therapy for AML or MDS. Exceptions for prior treatment of AML are (i.e., the following treatments are allowed):

  * Hydroxyurea for increased blast count (No washout period required. It can be continued throughout the first cycle of therapy).
  * Leukapheresis for leukocytosis (No washout period required. It can be continued during the study).
  * Preemptive treatment with retinoic acid prior to exclusion of APL \< 7 days.
* Participant who is receiving treatment with any other investigational agents.
* Participant requires treatment with concomitant drugs that are strong or moderate inducers of cytochrome P450 (CYP)3A or P glycoprotein (P-gp) during study treatment.
* Participant who has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit \<= 3 days prior to C1D1.
* Participant with a cardiovascular disability status of New York Heart Association (NYHA) Class \>= 3.
* Participant with mean QTcF \> 450 msec at screening based on local reading performed in triplicate.
* Participant with a history of Long QT Syndrome at screening.
* Participant has been diagnosed with another malignancy within 2 years prior to screening for the study, with the following exceptions:

  * Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
  * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
  * Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
  * Participants who are on maintenance therapy for malignancies with no evidence of active malignancy for \>= 2 years and the maintenance therapy can be discontinued.
* Participant who has an uncontrolled intercurrent illness including, but not limited to any of the following conditions:

  * Uncontrolled hypertension
  * Active, uncontrolled infection (viral, bacterial or fungal): An infection controlled with an approved or closely monitored antibiotic/antifungal treatment is allowed.
  * Symptomatic, congestive heart failure
  * Unstable angina pectoris
  * Chronic respiratory disease that requires continuous oxygen
  * Psychiatric illness/social situations that would limit compliance with study requirements
  * Any other illness or condition that would interfere with study compliance or would compromise the participant's safety or study endpoints, including any contraindications to gilteritinib, azacitidine or venetoclax listed in the country package insert.
* Participant who has gastrointestinal disorders, malabsorption or other abnormalities that would interfere with absorption of the oral study drug.
* Participant has active hepatitis B or C or other active hepatic disorder.

  * Participant with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B virus (HBV) deoxyribonucleic acid (DNA) are not eligible.
  * Participant with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if HBV DNA is undetectable.
  * For participant with a known history of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy, if indicated, to be eligible for this study.
  * Participant with antibodies to hepatitis C virus (HCV) will be eligible if hepatitis C ribonucleic acid (RNA) viral load is undetectable.
  * Participant with a known history of HCV infection must have been treated and cured to be eligible for this study. Participants with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load.
* Participant has had major surgery within 4 weeks prior to the first study dose.
* Participant has a known or suspected hypersensitivity to gilteritinib, azacitidine or venetoclax or any components of the formulations used.
* Participant with recent positive test for SARS-CoV-2 ( or diagnosed with COVID-19) and no follow up test with negative result cannot be enrolled. Participant with contact to persons with COVID-19 and participants with signs and symptoms for COVID-19 infection must be tested before enrolling.
* Participant who requires concomitant treatment with a strong or moderate P-gp or CYP3A iinhibitor, with the exception of posaconazole, for antifungal prophylaxis during cycle 1 of the Dose Ranging Phase (phase 1). Note: Posaconazole is the only strong CYP3A inhibitor antifungal allowed during the cycle 1 DLT evaluation period. Post-DLT evaluation period, other antifungals including strong or moderate CYP3A inhibitors are allowed throughout the study.
* Participant does not have any of the following mutations:

FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

Primary outcomes:
measure: Number of Participants with Dose Limiting Toxicities (DLTs)
timeFrame: Up to 42 Days
measure: Number of Participants with Adverse Events (AEs)
timeFrame: Up to 49 months
measure: Number of Participants with Serious AEs (SAEs)
timeFrame: Up to 49 months
measure: Number of Participants with laboratory value abnormalities and/or AEs
timeFrame: Up to 48 months
measure: Number or Participants with electrocardiogram (ECG) abnormalities and/or AEs
timeFrame: Up to 48 months
measure: Number of Participants with vital sign abnormalities and/or AEs
timeFrame: Up to 48 months
measure: Number of Participants with physical exam abnormalities and/or AEs
timeFrame: Up to 48 months
measure: Number of Participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status scores
timeFrame: Up to 48 months
measure: Percentage of Participants with Complete Remission (CR)
timeFrame: Up to 24 months
measure: Pharmacological activity by Plasma Inhibitory Activity Assay (PIA)
timeFrame: Up to 2 months
measure: Pharmacokinetics (PK) of ASP2215 in plasma: concentration
timeFrame: Up to 6 months
Secondary outcomes:
measure: Percentage of Participants with Complete Remission and Complete Remission with Partial Hematological Recovery (CR/CRh) rate
timeFrame: Up to 24 months
measure: Percentage of Participants with Composite Complete Remission (CRc)
timeFrame: Up to 24 months
measure: Duration of Remission (DOR)
timeFrame: Up to 24 months
measure: Duration of Overall Survival (OS)
timeFrame: Up to 24 months
measure: Duration of Event free survival (EFS)
timeFrame: Up to 24 months
measure: Pharmacokinetics (PK) of ASP2215 in plasma: area under the plasma concentration-time curve during a dosage interval (AUCtau)
timeFrame: Up to 6 months
measure: PK of ASP2215 in plasma: maximum observed concentration (Cmax)
timeFrame: Up to 6 months
measure: PK of ASP2215 in plasma: pre-dose trough concentration (Ctrough)
timeFrame: Up to 6 months
measure: PK of ASP2215 in plasma: area under the curve from time 0 to the time of the last measurable concentration (AUClast)
timeFrame: Up to 6 months
measure: PK of ASP2215 in plasma: time to Cmax (tmax)
timeFrame: Up to 6 months
measure: Number of participants with negative minimal residual disease (MRD) status
timeFrame: Up to 48 months
measure: Transplantation rate
timeFrame: 24 months
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Nat'l Medical Center
state: California
city: Irvine
country: United States
facility: Univ. of California - Irvine
state: California
city: Los Angeles
country: United States
facility: UCLA Medical Center
state: California
city: Denver
country: United States
facility: Sarah Cannon Research Institute
state: Colorado
city: Pembroke Pines
country: United States
facility: Memorial Cancer Institute
state: Florida
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Chicago
country: United States
facility: Robert H. Lurie Comprehensive Cancer Center
state: Illinois
city: Baltimore
country: United States
facility: University of Maryland
state: Maryland
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Bronx
country: United States
facility: Motefiore-Einstein Center for Cancer Care
state: New York
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
city: Winston-Salem
country: United States
facility: Novant Health
state: North Carolina
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Portland
country: United States
facility: Oregon Health and Science University
state: Oregon
city: Philadelphia
country: United States
facility: University of Pennsylvania-Abramson CCC-Dept. of Hem Onc
state: Pennsylvania
city: Philadelphia
country: United States
facility: Thomas Jefferson University Hospital
state: Pennsylvania
city: Houston
country: United States
facility: The University of Texas MD
state: Texas
city: Milwaukee
country: United States
facility: The Medical College of Wisconsin- Froedtert Hospital
state: Wisconsin
Study officials:
affiliation: Astellas Pharma Global Development, Inc.
name: Medical Director
role: STUDY_DIRECTOR
References: